Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colon Cancer: early-phase trial registry
34 of 99 indexed Colon Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #140 of 28,707 conditions by registered trial count.
99 US clinical trials · 34 currently recruiting · #140 of 28,707 conditions by registered trial count
Colon Cancer: 99 US clinical trials tracked, 34 recruiting.
Colon Cancer is the subject of 99 registered US clinical trials on ClinicalTrials.gov, 34 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition colon-cancer
OPEN 34 | RECR 34% | LATE 4 | EARLY 37 | RANK #140 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Stage IIIB Lung Cancer AJCC v8 (34% recruiting · 32 trials)
Colon Cancer lists 34 open slots (34% of 99 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Colon Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Colon Cancer is recruiting below its size-band peers.
34 of 99 indexed trials (34.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Colon Cancer trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 6 of 99 trials (6.1%). 73 distinct sponsors appear on at least one study for this condition label.
-
Typical Colon Cancer enrolment sits around 110 participants.
Median target enrolment is 110 among the 98 trials that report a genuine target (sentinel values excluded). 45 of those (45.9%) plan for fewer than 100 participants.
-
Colon Cancer research is mostly interventional.
76 interventional and 23 observational studies make up this index (76.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
99 total, page 1 of 2
Integrated Cancer Repository for Cancer Research
University of Nebraska
NCT02012699
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Avera McKennan Hospital & University Health Center
NCT05142033
Genomic Services Research Program
National Human Genome Research Institute (NHGRI)
NCT02595957
Collection of Blood From Patients With Cancer
National Cancer Institute (NCI)
NCT00034216
EXoPERT EMERALD Clinical Study
EXoPERT
NCT07186296
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
University of California, San Francisco
NCT05056077
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Washington University School of Medicine
NCT06340646
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
National Cancer Institute (NCI)
NCT00451022
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Memorial Sloan Kettering Cancer Center
NCT00582621
An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer
City of Hope Medical Center
NCT07255729
Adaptive Symptom Self-Management Immunotherapy Study
University of Arizona
NCT05715255
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
NCT04907643
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
NCT04916990
Resilience and Equity in Aging, Cancer, and Health (REACH)
Dana-Farber Cancer Institute
NCT04674267
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06682793
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
NCT06263088
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
NCT07127874
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics
NCT04678648
PrehabPal: A Digital Tool to Help Older Adults Prepare for Cancer Surgery
University of California, San Francisco
NCT05520866
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Sapience Therapeutics
NCT05848739
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06239194
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
National Cancer Institute (NCI)
NCT03190941
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
NCT04354064
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
Memorial Sloan Kettering Cancer Center
NCT04668872
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Cartography Biosciences
NCT07321106
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations
NCT07011576
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Rutgers, The State University of New Jersey
NCT05806931
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
M.D. Anderson Cancer Center
NCT05961709
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med
NCT05283330
Phase II Trial of Lung Chemoemobolization
City of Hope Medical Center
NCT05672108
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
University of Iowa
NCT05239546
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT06673329
COLON-MD: Colon Cancer Longitudinal Study
Baylor Research Institute
NCT04751448
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Washington University School of Medicine
NCT06904365
Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality
Exact Sciences Corporation
NCT04124406
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT00579514
Genomic Structural Variation in Cancer Susceptibility
Memorial Sloan Kettering Cancer Center
NCT00996710
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Eli Lilly and Company
NCT03157128
Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.
University of Colorado, Denver
NCT04739696
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
M.D. Anderson Cancer Center
NCT05677048
CRC Detection Reliable Assessment With Blood
New Day Diagnostics
NCT05551052
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
NCT00600496
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen
NCT04354246
RCT of Mobile Apps & FitBit v. Usual Care
Weill Medical College of Cornell University
NCT03623464
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics
NCT05864144
Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer
Emory University
NCT04780477
The Exercise And Colorectal Cancer Treatment Trial
Pennington Biomedical Research Center
NCT03975491
Improving Quality of Life for Colon Cancer Patients and Their Caregivers
University of Hawaii
NCT04713007
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Cancer Institute (NCI)
NCT04708470
Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients
The University of Texas Health Science Center at San Antonio
NCT02891538
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 11 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Colon Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Colon Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Colon Cancer page
99 registered trials, 34 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 34 Colon Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Colon Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colon Cancer condition card totals 99 registered trials; most-linked intervention Cemiplimab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.